Advertisement

Gastroenterologia Japonica

, Volume 20, Issue 3, pp 246–251 | Cite as

Sterol and bile acid metabolism after short-term prednisolone treatment in patients with chronic active hepatitis

  • Yasuhito Yamanishi
  • Yasuo Nosaka
  • Hironaka Kawasaki
  • Chisato Hirayama
  • Shiro Ikawa
Original Article

Summary

Serum levels of squalene, cholesterol and bile acid were measured before and after short-term prednisoIone administration in patients with chronic active hepatitis. Comparison with normal controls indicated that serum bile acid levels were increased significantly (p<0.01) in patients with chronic active hepatitis, but serum levels of squalene and cholesterol did not differ significantly between the two groups. After short-term prednisolone treatment, serum levels of squalene and cholesterol were increased significantly (p<0.01) as compared with the pretreatment level. On the other hand, while serum fasting bile acid levels were found to be increased significantly (p<0.01), serum clearance after oral administration of ursodeoxycholic acid improved significantly (p<0.05) after treatment. These results indicated that short-term prednisolone treatment increases sterol metabolism in the liver in patients with chronic active hepatitis, resulting from an increase in hepatic clearance of bile acids.

Key words

Squalene Bile acid Prednisolone UDCA tolerance test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Dietschy JM, et al: Cholesterol synthesis in the squirrel monkey: relative rates of synthesis in various tissues and mechanisms of control. J Clin Invest 47: 166, 1968PubMedCrossRefGoogle Scholar
  2. 2).
    Eriksson S: Biliary excretion of bile acids and cholesterol in bile fistula rats. Bile acids and sterols. Proc Soc Exp Biol Med (NY) 94: 578, 1957Google Scholar
  3. 3).
    Sandhofer F, et al: Cholesterol turnover in patients with chronic liver disease. Europ J Clin Invest 3: 10, 1973PubMedCrossRefGoogle Scholar
  4. 4).
    Adlersberg D, et al: Development of hyper-cholesteroremia during cortisone and ACTH therapy. JAMA 144:909, 1950Google Scholar
  5. 5).
    Oswald B, et al: The stimulation of the cholesterol synthesis in rat liver by hydrocortisone. Helv Chim Acta 59:2179, 1976CrossRefGoogle Scholar
  6. 6).
    Bagdade JD, et al: Steroid-induced lipemia. Arch Intern Med 125: 129, 1970PubMedCrossRefGoogle Scholar
  7. 7).
    Yamanishi Y, et al: Serum squalene levels in hepatobiliary diseases. Clin Chim Acta 88: 105, 1978PubMedCrossRefGoogle Scholar
  8. 8).
    Hirayama C, et al: Serum cholesterol and squalene in hepatocellular carcinoma. Clin Chim Acta 91: 53, 1979PubMedCrossRefGoogle Scholar
  9. 9).
    Yamanishi Y, et al: Oral ursodeoxycholic acid tolerance test in patients with digestive disease. Gastroenterologia Jpn 16: 472, 1981Google Scholar
  10. 10).
    Hirayama C, et al: Diagnostic significance of fasting serum bile acid in liver disease. Acta Hepato-Gastroenterol 23: 385, 1976Google Scholar
  11. 11).
    Shull HJ, et al: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84: 420, 1976PubMedGoogle Scholar
  12. 12).
    Cook GC, et al: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Quart J Med 40: 159, 1971PubMedGoogle Scholar
  13. 13).
    Soloway RD, et al: Clinical, biochemical and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63: 820, 1972PubMedGoogle Scholar
  14. 14).
    Murray-Lyon IM, et al: Controlled trials of prednisone and azathioprine in active chronic hepatitis. Lancet 7: 735, 1973CrossRefGoogle Scholar
  15. 15).
    Sandek CD, et al: Plasma squalene: Lipoprotein distribution and kinetic analysis. J Lipid Res 19: 827, 1978Google Scholar
  16. 16).
    McIntyre N: Plasma lipids and lipoproteins in liver disease. Gut 19: 526, 1978PubMedCrossRefGoogle Scholar
  17. 17).
    Nikkila EA: Lipid Metabolism, Obesity and Diabetes Mellitus edited by Levine R, et al. Gesrg Thieme Publ, Stuttgart 1974, p 29Google Scholar
  18. 18).
    Paumgartner G, et al: Serum bile acids and tolerance tests in liver disease. Barbara L, Dowling RH, Hofmann AF, Roda E eds. Bile acids in gastroenterology. MTP Press Limited, Lancaster1982, p 217Google Scholar
  19. 19).
    Ohkubo H, et al: Ursodeoxycholic acid oral tolerance test in patients with constitutional hyperbilirubinemias and effect of phenobarbital. Gastroenterology 81: 126, 1981PubMedGoogle Scholar
  20. 20).
    Mitropoulos KA, et al: The role of glucocorticoids in the regulation of the diurnal rhythm of hepatic βhydroxy β-methylglutaryl-Coenzyme A reductase and cholesterol 7α-hydroxylase. Biochem J 160: 49, 1976PubMedGoogle Scholar
  21. 21).
    Myant NB, et al: Cholesterol 7α-hydroxylase. J Lipid Res 18: 135, 1977PubMedGoogle Scholar
  22. 22).
    Scullard GH, et al: Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81: 987, 1981PubMedGoogle Scholar
  23. 23).
    Lam KC, et al: Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Eng J Med 304: 380, 1981CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Gastroenterology 1985

Authors and Affiliations

  • Yasuhito Yamanishi
    • 1
  • Yasuo Nosaka
    • 1
  • Hironaka Kawasaki
    • 1
  • Chisato Hirayama
    • 1
  • Shiro Ikawa
    • 2
  1. 1.Second Department of Internal MedicineTottori University School of MedicineYonagoJapan
  2. 2.Division of ChemistryInstitute of Steroid Research, Tottori University School of MedicineYonagoJapan

Personalised recommendations